Johnson & Johnson Acquires Intra-Cellular in $14.6 Billion Deal
Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...
Johnson & Johnson Tops Q4 EPS Forecasts
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
Johnson & Johnson (JNJ) Receives a Hold from Morgan Stanley
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a ...
Crain's Chicago Business6d
At 97, Chicago's pioneering Black capitalist reflects on a career spanning from Afro Sheen to 'Soul Train'
Gifting allows recipients to access the article for free. The hair-care company Johnson Products is justly celebrated as the first Black-owned company to go public, leading to a listing on the ...
Got $200? 2 Dividend Stocks to Buy and Hold Forever
These companies headline a $1.4 trillion industry, have staying power, and will pay you well to hold their stock.
Johnson & Johnson: Q4 Earnings Snapshot
Johnson & Johnson expects full-year earnings in the range of $10.50 to $10.70 per share, with revenue in the range of $89.2 billion to $90 billion. This story was generated by Automated Insights ( ...
Hosted on MSN22h
Johnson & Johnson Issues Guidance for Higher 2025 Results Following Fourth-Quarter Beat
Johnson & Johnson's (JNJ) fourth-quarter results topped market expectations while the healthcare products conglomerate anticipates results in 2025 to be higher than the previous year. The company sees ...